Business
Altimmune to Participate in Upcoming Investor Conferences
GAITHERSBURG, Md., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic diseases, today announced that management will participate and be available for one-on-one meetings at the following investor conferences: Wells Fargo Healthcare Conference in Boston, MA Friday, September 5, 2025 One-on-one meetings only H.C. Wainwright Global Investment Conference in New York, NY T
About this update from Altimmune, Inc.
GAITHERSBURG, Md., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic diseases, today announced that management will participate and be available for one-on-one meetings at the following investor conferences: About Altimmune Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of MASH, Alcohol Use Disorder (AUD), Alcohol-Associated Liver Disease (ALD) and obesity. For more information, please visit www.altimmune.com . Follow @Altimmune, Inc. on LinkedIn Follow @AltimmuneInc on X Company Contact: Greg Weaver Chief Financial Officer Phone: 240-654-1450 [email protected] Investor Contact: Lee Roth Burns McClellan Phone: 646-382-3403 [email protected] Media Contact: Jake Robison Inizio Evoke Comms Phone: 619-849-5383 [email protected] This press release was published by a CLEAR® Verified individual.